Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Eisai Co. Ltd (OP:ESALF)

30.61 +0.61 (+2.03%)

Streaming Delayed Price Updated: 9:30 AM EST, Jan 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	130
Open	30.61
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	30.00
Today's Range	30.61 - 30.61
52wk Range	22.51 - 35.83
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study ↗

January 24, 2025

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Via Benzinga

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement ↗

August 22, 2024

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated...

Via Benzinga

Performance

YTD	-4.3%	-4.3%
1 Month	+7.2%	+7.2%
3 Month	+0.8%	+0.8%
6 Month	+19.6%	+19.6%
1 Year	+23.1%	+23.1%

More News

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events ↗

July 26, 2024

Via Benzinga

Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings' ↗

July 15, 2024

Via Benzinga

Current Analysis: Eisai Co Ltd (ESAIY) ↗

July 16, 2023

Via Talk Markets

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst ↗

July 03, 2024

Via Benzinga

Why Is Eli Lilly Stock Trading Higher Premarket Tuesday? ↗

June 11, 2024

Via Benzinga

European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab ↗

March 22, 2024

Via Benzinga

Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer ↗

December 08, 2023

Via Benzinga

Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage ↗

October 13, 2023

Via Benzinga

LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly ↗

October 10, 2023

Via Benzinga

Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗

September 25, 2023

Via Benzinga

Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi ↗

September 25, 2023

Via Benzinga

Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer ↗

September 22, 2023

Via Benzinga

Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial ↗

August 25, 2023

Via Benzinga

Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts ↗

July 07, 2023

Via Benzinga

Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources ↗

June 13, 2023

Via Benzinga

Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote ↗

June 12, 2023

Via Benzinga

Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' ↗

June 08, 2023

Via Benzinga

FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval ↗

June 08, 2023

Via Benzinga

Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen ↗

May 04, 2023

Via Benzinga

Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! ↗

April 21, 2023

Via Benzinga

Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer ↗

April 10, 2023

Via Benzinga

National Institute on Aging Aims Building $300M Alzheimer's Research Database ↗

April 03, 2023

Via Benzinga

Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug ↗

March 31, 2023

Via Benzinga

Frequently Asked Questions

Is Eisai Co. Ltd publicly traded?

Yes, Eisai Co. Ltd is publicly traded.

What exchange does Eisai Co. Ltd trade on?

Eisai Co. Ltd trades on the OTC Traded

What is the ticker symbol for Eisai Co. Ltd?

The ticker symbol for Eisai Co. Ltd is ESALF on the OTC Traded

What is the current price of Eisai Co. Ltd?

The current price of Eisai Co. Ltd is 30.61

When was Eisai Co. Ltd last traded?

The last trade of Eisai Co. Ltd was at 01/14/26 09:30 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.